GleamWall
中文EN

HEPA Hepion Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1583771 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.4%
TTM EPS YoY98.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-166.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets180.2%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-120.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$134,654$50,918$70,000$0$0$423,277$22,235-$591,608
SG&A expense$1.42M$1.16M$728,509$609,683$527,902$919,488$1.26M$1.79M
Operating income-$1.55M-$1.21M-$798,509-$609,683-$527,902-$1.75M-$1.28M-$1.20M
Pretax income———-$656,885-$472,506-$1.04M-$6.11M-$1.55M
Income tax———————$0
Net income-$4.58M-$1.25M-$810,791-$656,885-$472,506-$1.04M-$6.11M-$1.55M
EBITDA———————-$1.20M
EPS (basic)-0.06-0.08-0.07—-0.04-0.09-2.15—
EPS (diluted)-0.06-0.08-0.07—-0.04-0.09-2.15—
Weighted avg. shares (diluted)71.14M16.19M11.62M—11.62M11.33M2.84M—
Balance sheet
Cash & equivalents$4.26M$1.63M$2.60M$1.83M$2.32M$2.92M$4.59M$406,408
Current assets$4.94M$1.93M$2.71M$3.07M$3.74M$4.51M$6.32M$1.61M
Total assets$5.01M$1.93M$2.71M$3.07M$3.74M$4.51M$6.32M$1.61M
Current liabilities$1.11M$492,759$735,572$299,383$347,411$592,854$935,924$3.14M
Short-term debt$299,582———————
Total liabilities$9.02M$648,923$848,747$402,405$415,808$708,531$2.42M$3.48M
Shareholders' equity-$4.02M$1.28M$1.86M$2.67M$3.32M$3.80M$3.90M-$1.86M
Shares outstanding100.07M29.12M11.62M11.62M11.62M11.62M9.59M139,168
Cash flow statement
Operating cash flow-$881,899-$1.39M$578,584-$332,775-$445,963-$1.38M-$1.12M-$1.15M
Investing cash flow———$0$0——$0
Financing cash flow$4.01M$420,000$195,934-$160,241-$157,354-$154,517$5.30M$0
Depreciation & amortization———————$0
Stock-based compensation———$0$0$0$20,783$28,625

Free plan shows the latest 8 periods; Pro shows all 53 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.